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Abstract
The locus coeruleus is the major source of noradrenaline to the brain and contributes to a wide range of physiological and
cognitive functions including arousal, attention, autonomic control, and adaptive behaviour. Neurodegeneration and
pathological aggregation of tau protein in the locus coeruleus are early features of progressive supranuclear palsy (PSP).
This pathology is proposed to contribute to the clinical expression of disease, including the PSP Richardson’s syndrome.
We test the hypothesis that tau pathology and neuronal loss are associated with clinical heterogeneity and severity in PSP.
We used immunohistochemistry in post mortem tissues from 31 patients with a clinical diagnosis of PSP (22 with
Richardson’s syndrome) and 6 control cases. We quantified the presence of hyperphosphorylated tau, the number of
pigmented cells indicative of noradrenergic neurons, and the percentage of pigmented neurons with tau-positive
inclusions. Ante mortem assessment of clinical severity using the PSP rating scale was available within 1.8 (±0.9) years for
23 patients.
We found an average 49% reduction of pigmented neurons in PSP patients relative to controls. The loss of pigmented
neurons correlated with disease severity, even after adjusting for disease duration and the interval between clinical
assessment and death. The degree of neuronal loss was negatively associated with tau-positive inclusions, with an
average of 44% of pigmented neurons displaying tau-inclusions.
Degeneration and tau pathology in the locus coeruleus are related to clinical heterogeneity of PSP. The noradrenergic
deficit in the locus coeruleus is a candidate target for pharmacological treatment. Recent developments in ultra-high field
magnetic resonance imaging to quantify in vivo structural integrity of the locus coeruleus may provide biomarkers for
noradrenergic experimental medicines studies in PSP.
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Introduction
The locus coeruleus is the principal source of noradren-
aline, with diverse influences on arousal, behaviour, move-
ment, and cognition [4]. The locus coeruleus is vulnerable
to neurodegeneration in several diseases including Alzhei-
mer’s disease, Parkinson’s disease, and progressive supra-
nuclear palsy (PSP) [1, 11, 24, 28, 50, 56]. Here, we focus
on the neuropathology of the locus coeruleus in PSP, a
complex parkinsonian syndrome characterised by postural
instability, falls, oculomotor impairment, cognitive, and
behavioural changes. We test the hypotheses that, in pa-
tients with clinical and pathologically confirmed diagnosis
of PSP, there is severe degeneration and tau-pathology in
the locus coeruleus, and that the degree of noradrenergic
cell loss relates to clinical severity.
The locus coeruleus is located in the posterior margin of
the rostral pons, near the lateral floor of the fourth ven-
tricle. Despite its small size, with only tens of thousands of
neurons in adult humans [1, 28, 34, 37, 40, 48], the locus
coeruleus sends widespread projections to the neocortex,
thalamus, and sub-cortical areas, sparing the majority of
the striatum. Its connectivity enables a concerted release of
noradrenaline in multiple target areas with modulatory
effects on several physiological and cognitive functions
including arousal, vigilance, sleep, attention, working-
memory, and adaptive behaviour (reviewed by [4, 14]).
Many of these functions are affected by PSP, over and
above the PSP’s classical movement disorder. The motor
and cognitive symptoms of PSP are not relieved by stand-
ard anti-parkinsonian medications including dopaminergic
therapies. However, there is evidence, from studies in Par-
kinson’s disease, that cognitive and behavioural deficits as-
sociated with locus coeruleus’ degeneration can be partially
restored by noradrenergic therapies [8, 27], raising the pos-
sibility of noradrenergic treatments in PSP.
At the neuropathological level, the degeneration of the
locus coeruleus in PSP includes neuronal loss and the
presence of neuronal and glial inclusions of hyperpho-
sphorylated 4-repeat isoforms of microtubule-associated
protein tau [45, 55]. In humans, the noradrenergic neurons
of the locus coeruleus contain a pigment called neurome-
lanin. Neuromelanin is synthesised through complex path-
ways involving iron- and copper-mediated oxidation of
cytosolic catecholamines into quinones. These accumulate
with proteins and lipids into autophagic organelles, which
fuse with lysosomes to form neuromelanin organelles [51,
60]. Although less is known about the synthesis of neuro-
melanin in the locus coeruleus than substantia nigra, the
pathways are likely to be similar [51], and may be neuro-
protective [31, 47]. The de-pigmentation of the locus coer-
uleus in PSP resulting from loss of neuromelanin-
containing neurons is so extensive that it is visible on gross
post mortem examination of the brain. Recently, the devel-
opment of high-resolution magnetic resonance imaging
(MRI) sequences [44], sensitive to the paramagnetic fea-
tures of neuromelanin [58], has renewed the interest in de-
veloping biomarkers for assessing the in vivo degeneration
of the locus coeruleus in neurodegenerative diseases in-
cluding PSP [7]. However, before these MRI methods can
be further developed, it is necessary to quantify the neur-
onal loss in the LC ex vivo and determine whether this
pathology relates to other neuropathological aspects in
PSP such as the proportion of tau-positive inclusions, and
to clinical severity.
Therefore, we quantified the locus coeruleus neuro-
pathology in complementary ways. First, we estimated
the total number of pigmented neurons post mortem in
PSP patients in relation to a group of controls of similar
age. Second, we estimated the number of pigmented
neurons in the locus coeruleus that manifested neuronal
inclusions comprising aggregated hyperphosphorylated
tau. Third, we tested the correlations between patho-
logical and clinical ratings. We confirm the severe loss
of locus coeruleus neuron number, and a high rate of
tau inclusions [20, 39], with a correlation between ante
mortem disease severity (adjusting for time between lat-
est clinical assessment and death), and the severity of
neuronal loss in the locus coeruleus.
Materials and methods
Brainstem tissue from patients and controls was obtained
through the Cambridge Brain Bank at the Cambridge
University Hospitals NHS Trust, UK (under the ethically
approved protocol for “Neurodegeneration Research in
Dementia”) and normative cognitive data from the PiPPIN
cohort (“Pick’s disease and progressive supranuclear palsy
prevalence and incidence study” [17]). Thirty-one patient
donations were received between 2010 and 2017 from pa-
tients with a clinical and pathological diagnosis of PSP.
The available fixed tissue blocks for two PSP-cases did not
include the entire locus coeruleus so for these two we only
report their percentage of pigmented neurons positive for
tau-inclusions. Moreover, in two other cases, no immuno-
histochemistry could be performed because tissue sections
detached from the glass slide.
The neuropathological diagnosis of PSP was based on
the National Institute of Neurological Disorders and
Stroke (NINDS) criteria. Clinical diagnoses were made
according to the revised MDS 2017 criteria (Höglinger
et al., 2017), based on the final clinical review (see Gaz-
zina et al. for details [22]). This led to diagnoses of prob-
able PSP-Richardson’s syndrome in n = 22, possible PSP
with predominant speech/language disorder (PSP-SL) in
n = 2, and possible PSP with predominant corticobasal
syndrome (CBS) in n = 7.
Many of the PSP patients had also participated in lon-
gitudinal cohorts studies at the Cambridge Centre for
Frontotemporal Dementia and Related Disorders [17,
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30]. Clinical, cognitive, and behavioural assessments in-
cluded the PSP rating scale (PSPRS) [23], revised Adden-
brooke’s cognitive examination (ACE-R) [36], Mini
Mental State Examination (MMSE) [21], and revised
Cambridge Behavioural Inventory (CBI-R) [52]. The
PSPRS was available within 3 years of death for n = 19
cases of PSP-Richardson’s syndrome, n = 2 PSP-CBS and
n = 1 PSP-SL. For control tissue, we examined six Brain
Bank donors with no history of neurological or psychi-
atric illness and of similar age and sex as PSP cases. Ante
mortem clinical and cognitive data for control brain do-
nors were not available. However, we compared the cog-
nitive profile of the PSP patients to a control population
of elderly individuals (n = 60) recruited in a regional epi-
demiological study [17].
Group ages, brain weight, and cognitive scores were
compared with two-samples independent t-test (Tables 1
and 2). Sex differences between groups were tested using
Fisher’s exact test (Table 1).
Tissue processing and immunohistochemistry
The brain was removed at autopsy and the left cerebral
hemisphere, left hemi-brainstem, and left cerebellum
were fixed in 10% neutral buffered formalin for 2–3
weeks. For diagnostic purposes immunohistochemistry
was performed on sections from brainstem, subcortical,
cerebellum, archicortex and cerebral regions to identify
the characteristic protein aggregates and pathological
features of PSP and confirm the diagnosis post mortem.
The initial diagnostic immunohistochemistry had used
antibodies targeting Tau11/57 (from 2010 to mid-2016),
or AT8 (from mid-2016 to 2017; MN1020, Thermo Sci-
entific, USA). To exclude significant co-pathologies, add-
itional immunohistochemistry included hippocampal
and temporal neocortical beta-amyloid (Clone 6F/3D,
M0872, Dako, Denmark). For those cases who had come
into the brain bank between 2010- mid-2016 (n = 24)
the presence of lewy bodies was assessed in all areas on
the H&E slides, and screening for ubiquitin (Z0458,
Dako, Denmark) in hippocampal and temporal neocor-
tex. This ubiquitin antibody also stained TDP-43 inclu-
sions. Cases dying after mid-2016 (n = 7) were stained
for medullary alpha-synuclein (SA3400, Enzo life sci-
ences, USA) and hippocampal and temporal neocortical
TDP-43 (TIP-PTD-P02, Cosmo Bio Co LTD, Japan).
To ensure that the entire locus coeruleus was available
for the estimation of numbers of neurons, the diagnostic
blocks containing the pons and lower midbrain were re-
trieved and added to the fixed samples containing the
locus coeruleus. Brain tissue were embedded in paraffin
and cut at 10 μm on a rotary microtome and mounted
on SuperFrost Plus™ Adhesion Microscope Slides
(J1800AMNZ, ThermoFischer Scientific, USA). For each
individual case, every 100th section was immunostained
for hyperphosphorylated tau (AT8) to visualise patho-
logical tau aggregates. In brief, sections were deparaffi-
nised in xylene and hydrated in progressively decreasing
concentrations of alcohol and rinsed in running water.
Antigen retrieval was performed at room temperature by
incubating for 5 min in formic acid (33015–2.5 L-M,
Sigma-Aldrich, Germany), and blocked in 5% normal
rabbit serum, before incubating with the primary anti-
body (AT8 1:500, MN1020, Thermo Scientific, USA) for
1 h at room temperature. Sections were subsequently in-
cubated with Polyclonal Rabbit Anti-Mouse Immuno-
globulins/Biotinylated (E0354, Dako, Denmark) in 10%
human serum and developed using the VECTASTAIN
ELITE ABC Kit Avidin Biotinylated HRP Complex (PK-
Table 1 Demographic and clinical characteristic of patients with PSP, and pathology-controls
PSP (n = 31) PSP-RS (n = 22) Variant PSP (n = 9) Controls (n = 6) p-value Control – PSP
Age (years) at Death
Mean ± SD 75.4 ± 7.4 73.2 ± 7.1 80.7 ± 5.1 70 ± 5.6 n.s.a
(Range) (63–90) (63–90) (73–90) (62–77)
Number (%) of males 19 (61%) 14 (63%) 5 (56%) 2 (33%) n.s.b
Age (years) at symptom onset
Mean ± SD 71.5 ± 8.3 66.0 ± 8.2 73.7 ± 5.5 – –
(Range) (51–86) (51–86) (68–86)
Disease duration (years)
Mean ± SD 6.9 ± 2.9 7.0 ± 2.8 6.9 ± 3.3 – –
Range (3.1–15.5) (4.2–15.5) (3.1–14.3)
Brain weight (g)
Mean ± SD 1196 ± 142.7 1193 ± 151.5 1209 ± 117.7 1222 ± 47.8 n.s.a
Range (960–1500) (960–1500) (1079–1400) (1153–1263)
PSP progressive supranuclear palsy, SD standard deviation, n.s. not significant, p > 0.05 uncorrected, by a Student’s t-test or b Fischer’s exact test, Subscript to t is
degrees of freedom
Kaalund et al. Acta Neuropathologica Communications            (2020) 8:11 Page 3 of 11
6100, VECTOR laboratories, USA) to yield a purple re-
action product. Sections were counter stained with Vec-
tor Methyl green (H-3402-500, Vector laboratories,
USA) to allow good visual discrimination between cell
nuclei, tau aggregates, and endogenous neuromelanin
(Fig. 1).
Quantification of pigmented neurons in locus coeruleus
A 2D design was used to estimate the total number of
pigmented neurons (StereoInvestigator 11.0 64bit,
Microbrightfield, USA) using an Olympus BX-53 micro-
scope coupled with a Prior H128 computer-controlled
x-z-y motorized stage and a high sensitivity Hitachi
3CCD video camera system. The locus coeruleus was
outlined at 4x magnification and counting within 100%
of that area was performed under a 20X objective. Pig-
mented neurons were defined by the presence of neuro-
melanin, which appears as brown granular staining
within the cytoplasm of medium and large neurons in
the locus coeruleus. When an AT8-positive aggregate
was present in these pigmented neurons, the neuron was
counted as tau immunoreactive. A neuron was counted
when either the nucleolus or a well-defined nucleus was
in focus (Fig. 1).
The number of pigmented neurons was calculated by
multiplying the number of neurons counted in the serial
sections by 100 (the sampling frequency). As sections
were 10 μm and we counted pigmented neurons in the
entire cross-sectional area of locus coeruleus on each
section, the height and area fractions were 1. Using this
sampling scheme, an average of 9 sections were counted
in controls, and an average of 7 sections in PSP. The
proportion of neurons with hyperphosphorylated tau-
inclusions was determined by dividing the number of
pigmented neurons positive for hyperphosphorylated
tau-inclusions by the total number of pigmented
neurons.
Quantification of total tau burden in the locus coeruleus
The overall burden of pathological tau in the locus coer-
uleus was estimated as the percentage of pixels associ-
ated with tau staining within the locus coeruleus area,
using the build-in “positive pixel count” in QuPath
(0.2.0.m5). Micrographs of the locus coeruleus were ac-
quired from the serial sections used for neuronal esti-
mates under a 20X objective. A series of images were
uploaded in QuPath, next, the area of the locus coeru-
leus was manually outlined, and stain vectors for neuro-
melanin, tau, and background signal were adjusted for
each section. The percentage of ‘tau’ positive pixels
within the region of interest was measured using the fol-
lowing settings in the “positive pixel count”-algorithm:
Down-sample factor = 1.0, Gaussian sigma = 2, neurome-
lanin threshold (negative) = 0.2, tau threshold (positive) =
0.2.
We used weighted least-square regression to examine
the correlation between the number of pigmented neu-
rons and PSPRS, ACER, MMSE, or CBI scores, and the
relationship between the percentage of pigmented neu-
rons with tau-inclusion and PSPRS score. To adjust for
the difference in time between the last clinical assess-
ment and death in relation to total disease duration, we
Table 2 Demographic and cognitive characteristics of the PSP patients and healthy controls from the “PiPPIN” regional
epidemiological study
PSP patients (n = 31) PSP-RS (n = 22) Variant PSP (n = 9) Controls (PiPPIN) (n = 60) p-value Control – PSP
Age at testing
Mean ± SD 73.3 ± 7.7 71.02 ± 7.3 79.9 ± 5.6 71.4 ± 6.0 n.s.a
Number (%) of males 19 (61%) 14 (63%) 5 (56%) 30 (50%) n.s.b
Interval to death (year)
Mean ± SD 1.8 ± 0.9 2.2 ± 0.8 1.8 ± 0.8 – –
PSPRS n = 23 n = 19 n = 3
Mean ± SD 48.9 ± 14.1 47.9 ± 14.1 55 ± 15.1 0.32 ± 0.99 t45 = 17.2, p = 2.2e
− 21
ACER
Mean ± SD 64.2 ± 16.0 65.0 ± 15.0 62.4 ± 19.2 95.7 ± 4.4 t89 = 14.3, p = 9.5e
− 25
CBI-R n = 24 n = 17 n = 7
Mean ± SD 84.5 ± 52.7 83.6 ± 52.1 86.4 ± 52.7 6.8 ± 7.3 t82 = 11.3, p = 2.6e
− 18
MMSE
Mean ± SD 21.9 ± 4.8 22.3 ± 4.4 21 ± 5.8 29.4 ± 0.9 t89 = − 11.6, p = 1.4e
− 19
For PSPRS and CBI-R the n above the mean indicates the number of patients from which data was available. The controls were healthy, age and sex-matched
controls from a regional population cohort, PiPPIN [17]. PSP progressive supranuclear palsy, PSP-RS PSP Richardson’s syndrome, PiPPIN “Pick’s disease and
progressive supranuclear palsy prevalence and incidence study” [17], PSPRS PSP rating scale, ACER revised Addenbrooke’s cognitive examination, CBI-R revised
Cambridge Behavioural Inventory, MMSE Mini Mental State Examination, SD standard deviation, n.s. not significant, p > 0.05, by a Student’s t-test or b Fischer’s
exact test. Subscript to t is degrees of freedom. Uncorrected p-values
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included the time between clinical assessment and death
as percent of disease duration (100*(1-“interval between
testing and death”/"disease duration”)) (these values repre-
sented weights in the linear regression analyses). To test
for an association between the number of pigmented neu-
rons and the macroscopic scoring of locus coeruleus pal-
lor, we used analysis of variance (ANOVA). Finally,
Pearson’s correlations were used to test for associations
between (i) the total number of pigmented neurons and
the percentage of pigmented neurons with tau-inclusions,
(ii) the pathological measures, disease duration, disease
severity or other cognitive and neuropsychiatric mea-
sures, and (iii) total tau burden. A p-value< 0.05 was
considered significant.
Results
Table 1 summarises the clinical, demographic, and gross
pathological characteristics of the brain donors. There
were no significant differences in age, sex or brain weight
between the PSP and pathology control cases. The control
group from the PiPPIN epidemiological study was similar
to the PSP group in terms of age and sex. However, as ex-
pected, PSP patients scored higher on the PSPRS and CBI,
and lower on the ACE-R and MMSE than controls from
the PiPPIN study (Table 2).
Five of the 31 patients in the present study, 16%, had
co-pathology; 4 with amyloid beta, 0 with alpha-
synuclein, 0 with TDP-43 and 1 with ubiquitin-poisitve
TDP-43- and tau-negative inclusions in the hippocam-
pus. The level of co-pathology was within limits of what
can be expected as age related pathology in all cases.
The mean total number of pigmented neurons in the
locus coeruleus was 50.6 × 103 in controls (SD 1.4 × 103)
and 26.2 × 103 in PSP patients (SD 1.4 × 103). This 49%
reduction of pigmented neurons in PSP patients was sig-
nificant (t = 3.96, df = 33, p = 0.0004, Fig. 2a).
Disease severity, as measured by total-PSPRS, was
negatively correlated to the number of pigmented neu-
rons (F(1,19) = 5.9, t = − 2.4, p = 0.026; Fig. 2b). The total
number of pigmented neurons in the locus coeruleus
did not correlate with disease duration (Pearson’s correl-
ation, r = − 0.22, p = 0.26) or age (Pearson’s correlation,
r = − 0.24, p = 0.16). We did not observe a significant
correlation between the number of pigmented neurons
and ACER (F(1,28) = 0.72, p = 0.40), MMSE (F(1,28) =
0.99, p = 0.33) or CBI (F(1,21) = 1.45, p = 0.24). The
Fig. 1 Representative images of locus coeruleus in control and PSP cases. a Photographs of pons sections including the locus coeruleus (arrows).
b Micrographs showing the location of locus coeruleus near the floor of the 4th ventricle in a control and PSP case (red arrows). Stitched images
from micrographs taken using a 4X objective. c Micrographs taken using a 20X objective, red arrows indicate representative examples of
pigmented neurons of the locus coeruleus and hollow red arrows indicate examples of pigmented neurons with tau-inclusions. b and c Sections
were stained for hyperphosphorylated tau (AT8) in purple using methyl green as counterstain, endogenous neuromelanin shown in brown
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macroscopic scoring of locus coeruleus pallor was not
significantly related to the microscopic counting of the
number of pigmented cells (F(2,21) = 1.37, p = 0.28).
The pigmented neurons positive for hyperphosphory-
lated tau were observed in four out of six controls, but
the percentage of such neurons relative to total number
of pigmented neurons was only 3% (range 0.5 to 9%). In
PSP, the average percentage of pigmented neurons posi-
tive for hyperphosphorylated tau was 44% (range 6 to
63%). The increase in the number of pigmented neurons
with tau-inclusions in PSP was significant (t = − 7.26,
df = 33, p = 2.5e− 8) (Fig. 2c). The percentage of pigmen-
ted neurons with tau-inclusions was not associated with
PSPRS (F(1,19) = 0.15, t = 0.39, p = 0.71). However, the
percentage of neurons positive for hyperphosphorylated
tau positively correlated with the total number of
neurons in PSP patients (Pearson’s r = 0.51, p = 0.007)
(Fig. 2d). Last, the number of pigmented neurons was
not significantly correlated with total tau burden in the
locus coeruleus (Pearson’s r = 0.096, p = 0.66).
Discussion
This study demonstrates severe neurodegeneration in
the locus coeruleus in PSP, with an average 49% reduc-
tion in the total number of pigmented neurons that are
the principal source of noradrenaline to the brain. The
total number of noradrenergic and neuromelanin-
containing cells in PSP correlated negatively with disease
severity, with fewer cells in those patients who had more
severe disease at the last ante mortem clinical assess-
ment. However, neuronal loss was not associated with
age or disease duration, which suggests a possible role of
Fig. 2 Loss of pigmented neurons in the locus coeruleus in PSP. a Combined scatter and boxplots showing the total number of pigmented
neurons in the left locus coeruleus in controls and patients. b There was a negative correlation between the number of pigmented neurons and
the PSP rating scale (PSPRS) (n = 20, weighted least-square regression F(1, 19) = 5.9, p = 0.026)). The dot size for each individual scales with interval
from assessment to death as a function of disease duration. c The percentage of pigmented neurons with tau-inclusions in controls and PSP. d
The positive correlation between the number of pigmented neurons and number of pigmented neurons with tau-inclusions. Each dot represents
an individual case, and for PSP cases (a-d), different colours of the dot represent specific PSP clinical phenotypes, i.e., black – probable PSP
Richardson’s Syndrome, grey – possible PSP-SL, white – possible PSP-CBS. The lower and upper hinges of the grey boxes show the 25th and 75th
percentiles, while the horizontal bar represent the median values. Whisker-plots display the range of data within 1.5 of the inter-quartile range,
indicating that no extreme outlying values were observed. The linear regression lines are plotted in panel b and d
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the locus coeruleus degeneration in mediating clinical
severity rather than simply reflecting an age-related effect
or a consequence of a more prolonged disease course.
The average percentage of pigmented neurons with hyper-
phosphorylated tau-inclusions in PSP was 44%, but this
fraction was lower in PSP patients with more severe total
neuronal loss. This suggests either a non-linear dynamic
relationship between tau-aggregation and cell death, or
the presence of a subset of pigmented neurons with low
susceptibility to tau aggregation and death.
The average 49% loss of pigmented neurons that we
found in this study is highly consistent with the 53% and
51% reduction of medium-to-large neurons in the locus
coeruleus reported in two previous studies [33, 39]. How-
ever, another semi-quantitative study, in which neurons
positive for tyrosine hydroxylase were counted in single
sections in the upper pons, did not report a significant loss
of neurons in the locus coeruleus in PSP [20]. The differ-
ences across the studies may be due to the focus on the
rostral pons rather than on the entire locus coeruleus, and
to other possible differences in how the noradrenergic
cells were defined and counted. In the present study, the
neuromelanin-containing neurons were assumed to repre-
sent the entire noradrenergic neuronal population in the
locus coeruleus. This is because the presence of the neu-
romelanin in the locus coeruleus cells is a consequence of
excess catecholamines in the cytosol, which is in turn
linked to the synthesis of the noradrenaline and its pack-
ing in synaptic vesicles [3, 4].
Another way to identify the locus coeruleus cells produ-
cing noradrenaline is via the immuno-staining for tyrosine
hydroxylase, the enzyme that converts L-tyrosine to L-
DOPA before the conversion of L-DOPA to noradrenaline.
Immunohistochemistry against the dopamine beta-
hydroxylase, the enzyme that transform dopamine into
noradrenaline, can also be used. These two biochemical
markers are expressed by the same neuronal population
[15] i.e., the noradrenergic cells that constitutes more than
95% of neurons in the locus coeruleus [2, 39]. However, a
proportion of tyrosine hydroxylase positive neurons, which
are more numerous in the rostral than caudal pons, lack
pigmentation [2, 15, 25]. The number of such neurons is
limited in relation to the total neuronal number in the
locus coeruleus [2, 15, 25]. Therefore, despite potential dif-
ferences in the methods for identifying noradrenergic neu-
rons, the findings from different pathological cohorts were
in keeping with a significant reduction of noradrenergic
neurons in PSP.
Our second hypothesis was that the loss of LC pig-
mented neurons relates to disease severity, measured via
the PSPRS. This was confirmed. The PSPRS is the most
widely used clinical scale of disease severity and progres-
sion in PSP, in observational studies and clinical trials. It
encompasses diverse domains of symptoms and signs
that are typically endorsed by PSP patients and their
carers, including behavioural, gait, mobility, bulbar, limb,
and oculomotor problems. Other disorders and even nor-
mal aging can influence the total PSPRS score [23], but in
the context of PSP clinical syndromes, the PSPRS has high
internal consistency and replicability across different
countries (e.g., there is a typical 10–12 points decline per
year in Richardson’s syndrome) [9, 23]. The total score
and domains of the PSPRS have been associated with
PSP-related regional atrophy in the brainstem [18, 26, 49,
54] but not yet related to specific brainstem nuclei as the
locus coeruleus [38] or in vivo tau pathology as measured
via positron-emission tomography [19, 54].
The association between the locus coeruleus integrity
and disease severity raises the possibility of noradrener-
gic treatment strategies [41]. One study reported that
alpha 2 noradrenergic receptor antagonism did not alle-
viate motor symptoms in PSP [43]. However, there is
more favourable evidence, from studies in Parkinson’s
disease (PD), that the noradrenalin reuptake inhibitor
atomoxetine can improve motor control and executive
functions in a subset of patients [8, 27, 57]. The relation-
ship between the loss of pigmented neurons in the locus
coeruleus and disease severity calls for a stratified ap-
proach in clinical trials, which might exploit emerging
imaging biomarkers of LC structural integrity. Currently,
non-invasive methods to quantify the in vivo LC structural
integrity, via the susceptibility of the MRI signal to the
paramagnetic effects of neuromelanin, are emerging as
promising tools for neurodegenerative disorders, especially
at ultra-high field [5, 44]. The association between post
mortem depigmentation and the neuromelanin-related
MRI signal in the LC may therefore provide support for
in vivo biomarkers for noradrenergic dysfunction in PSP.
This could facilitate the monitoring of the disease progres-
sion and treatment response [7, 42].
Not all pigmented neurons in the locus coeruleus are
equally affected by PSP. On average, 44% of the pigmen-
ted neurons had tau-inclusions. This accords with a
semi-quantitative study showing tau inclusions in 42% of
the noradrenergic neurons [20], and the presence of tau
inclusions in 77% of the noradrenergic neurons counted
using stereology [39]. The current cohort was larger
than those employed in previous studies and found high
variability, 6–63%, of LC neurons having tau-inclusions.
This implies that differences between our findings and
previous results might depend on the use of different
sample sizes with variable estimates. Differences in the
analytical procedures used or in the demographic char-
acteristics of the cohorts may also have contributed to
the different percentages of tau-positive neurons across
studies. We found a significant positive correlation be-
tween the percentage of pigmented neurons with tau-
inclusions and the total number of pigmented neurons.
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However, the percentage of the pigmented neurons with
tau-inclusions was not associated with disease severity.
These results are consistent with the hypothesis that the
accumulation of tau precedes and contributes to the
neuronal death [53], with differential susceptibility to
cell death with tau-positive neurons as the disease pro-
gresses, or as a result of subtypes of pigmented neurons.
Dying neurons may also release extra cellular neurome-
lanin and trigger microglia activation and inflammation,
as observed in the substantia nigra in Parkinson’s disease
[29, 35] and consistent with the co-localisation of acti-
vated microglia and tau pathology in PSP [32]. Nigral
microglia are able to phagocytose and degrade neurome-
lanin, but in doing so release hydrogen peroxide and
pro-inflammatory cytokines [59], which may lead to fur-
ther neuronal death. Neurodegeneration within the locus
coeruleus could thus be augmented through similar tau-
independent mechanisms.
The current data can also be compared to those reported
in the tauopathy of Alzheimer’s disease, in which the
neurofibrillary tangles in the locus coeruleus are present at
the pre-symptomatic Braak stages I and II [10, 12, 13, 28,
48]. In Alzheimer’s there is severe neuronal loss from
Braak stage III onwards [1, 13, 28, 48]: from 13 to 30% in
mild cognitive impairment and Braak stage I-III [1, 28],
to 45–50% in Braak stages IV-V [1, 28, 40], and 70–75% at
Braak stages V and VI [1, 39]. As in PSP, cell loss in the
locus coeruleus correlates with ante mortem global cogni-
tion in Alzheimer’s disease [1, 28]. We find an average loss
of 49% of pigmented neurons in PSP, but the case-
specific loss ranged widely, in proportion to the severity of
disease (PSP rating scale). Noradrenergic projections from
the locus coeruleus reach widespread cortical and subcor-
tical targets, that are differentially affected by Alzheimer’s
disease, PSP, and other degenerative disorders. We suggest
that whereas the degree of noradrenergic loss in Alzhei-
mer’s and PSP is similar, the functional consequences are
in part determined by additional pathology in the regions
receiving noradrenergic inputs. In contrast to the correl-
ation between the percentage of pigmented neurons with
tau-inclusions and neuronal loss we observed in PSP, the
percentage of noradrenergic neurons with intracellular
neurofibrillary tangles does not correlate with the total
number of locus coeruleus neurons in Alzheimer’s disease
[13]. This difference may depend on the different tau iso-
forms present in AD and PSP. Future studies addressing
the causal relationships between tau inclusions, neuronal
loss, noradrenergic signalling in the locus coeruleus in PSP
and other neurodegenerative disorders will help to refine
future interventional studies.
The present study has several limitations. First, as the
selection of cases was based on the post mortem neuro-
pathological diagnosis of PSP, we lack the PSP rating
scale in some cases with clinical diagnosis of PSP-CBS.
Second, as the PSP rating scale was necessarily obtained
ante mortem, the interval between clinical and cognitive
testing and death varied between patients, although we
sought to mitigate this issue by including, in our statis-
tical models, the interval between the last assessment
and death (in terms of percentage of total disease dur-
ation). The association between pigmented neurons and
PSP rating scale remained significant with and without
this weighting in the statistical model. Third, as we only
focused on the locus coeruleus pathology in PSP, we
cannot exclude a priori that the association between the
PSP rating scale and locus coeruleus pathology reflect a
more general association with neurodegeneration at sec-
ondary sites, including the targets of LC innervation.
Fourth, in the present study we counted the pigmented
cells in the locus coeruleus in serial sections selected
using systematic sampling. We counted cells on the
series of 2D sections rather than 3D, which is necessary
for a true unbiased stereological method. Our estimates
are therefore not unbiased and may be skewed towards
overestimation as the section thickness is less than the
average diameter of pigmented cells [16]. Further, in a
2D fractionator larger particles will have a greater
chance of being sampled [46], which may contribute fur-
ther to an overestimation bias. We estimated the total
number of pigmented neurons to 56,000 in the left locus
coeruleus in controls. This estimate is larger than what
has been reported in a number of stereological studies
that estimated the unilateral number of pigmented neu-
rons to range between 16,000–19,000 [1, 28, 34, 37, 40] .
However, Theofilas et al. [48] used stereology to esti-
mate the total number of mid- to large neurons in the
locus coeruleus in 68 aged individuals from Braak-stage
0 –VI. They observed a mean of 46,500 mid- to large
sized neurons in Braak stage 0, and a total range across
all Braak stages from 6674 to 137,910 neurons. Differ-
ences in the stereological methodologies e.g. the physical
vs. the optical disector or optical fractionator, which cell
populations was counted e.g. pigmented [1, 34, 37, 40],
tyrosine hydroxylase expressing [28] or size [48], and
whether one counts the soma profile or nucleolus may
contribute to the discrepancy between studies. Recogniz-
ing the inherent potential for biased estimates using a
2D fractionator design, we assume that this bias is con-
stant across subjects and thus does not invalidate the
correlations between neuronal numbers and tau-load or
disease severity.
Conclusions
To conclude, we provide evidence for severe degener-
ation in the locus coeruleus in PSP, and an association
between the number of noradrenergic neurons contain-
ing neuromelanin and disease severity. However, neur-
onal loss does not appear to be a simple function of age,
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disease duration or the presence of hyperphosphorylated
tau-inclusions. The use of the neuromelanin pigment to
identify post mortem the noradrenergic cells in the LC
also supports the development of non-invasive in vivo
neuroimaging markers that exploit the MRI signal linked
to the presence of neuromelanin [6]. The degeneration
of the locus coeruleus may be relevant to the develop-
ment of better stratification procedures in clinical trials.
Our study also highlights the importance of considering
noradrenergic restoration as a potential treatment for
PSP.
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